Evidence map›Paper›PMID 42218300›Full record

ArticleOncogene2026

Specifically targeted engineered exosomes loaded with circAKR1A1 enhance tumorigenesis and metastasis in prostate cancer by activating the PI3K/Akt signalling pathway.

Shenglong Li, Yue Kang, Yujing Guan, Jiahang Li, Runze Jiang, Shouyi Zhang, Enduo Qiu, Tianfu Wang, Rui Liu, Shanlin Wang and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shenglong Li *Second Ward of Bone and Soft Tissue Tumor Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China. lishenglong@cancerhosp-ln-cmu.com.ORCID http://orcid.org/0000-0003-2244-1184
Yue Kang *Department of Breast Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China.
Yujing GuanSecond Ward of Bone and Soft Tissue Tumor Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China.
Jiahang LiSecond Ward of Bone and Soft Tissue Tumor Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China.
Runze JiangSecond Ward of Bone and Soft Tissue Tumor Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China.
Shouyi ZhangDepartment of Urology, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China.
Enduo QiuSecond Ward of Bone and Soft Tissue Tumor Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China.
Tianfu WangSecond Ward of Bone and Soft Tissue Tumor Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China.
Rui LiuSecond Ward of Bone and Soft Tissue Tumor Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China.
Shanlin WangSecond Ward of Bone and Soft Tissue Tumor Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China.
Cong NingDepartment of Breast Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China.
Xing NiuChina Medical University, Shenyang, Liaoning, China.ORCID http://orcid.org/0000-0001-8834-792X
Yuming WangSecond Ward of Bone and Soft Tissue Tumor Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China. 13304013788@163.com.ORCID http://orcid.org/0009-0000-3973-2725
Yu ZengDepartment of Urology, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China. zengyud07@foxmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Determining effective treatment strategies for prostate cancer patients with bone metastasis remains a difficult issue. Targeted engineered exosomes have the potential to deliver anticancer drugs to tumor sites in a highly efficient and precise manner while minimizing treatment-related side effects. Here, we assessed the function and value of targeted engineered exosomes loaded with circAKR1A1 (OE-circAKR1A1-exosomes) in bone metastatic prostate cancer cells. The function and underlying mechanism of OE-circAKR1A1-exosomes were investigated via in vivo and in vitro experiments. We observed a positive correlation between circAKR1A1 expression and prostate cancer metastasis and progression. Both in vivo and in vitro experiments confirmed that OE-circAKR1A1-exosomes specifically targeted prostate cancer cells in the bone microenvironment. This targeting mechanism activated the PI3K/Akt signalling pathway, thereby facilitating tumor invasion and metastasis. Collectively, our findings suggest that circAKR1A1 is a driver and treatment target for metastatic prostate cancer. Targeted delivery of therapeutic circRNAs via engineered exosomes represents a highly promising clinical therapeutic approach. The schematic diagram of this study E3 aptamer-modified engineered exosomes loaded with circAKR1A1 specifically target bone metastases in PCa, thereby activating the PI3K/Akt signalling pathway to facilitate tumor invasion and metastasis.

Indexed as

Bone NeoplasmsCarcinogenesisExosomesPhosphatidylinositol 3-KinasesProstatic NeoplasmsProto-Oncogene Proteins c-aktRNA, CircularAnimalsCell Line, TumorCell ProliferationHumansMaleMiceNeoplasm MetastasisSignal TransductionPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, Circular

Identifiers

PMID42218300

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.